<DOC>
	<DOC>NCT00784966</DOC>
	<brief_summary>The purpose of this study is to determine if prolonged administration of the anti TNF (tumor necrosis factor)-Alpha agent etanercept is associated with enhanced graft survival in patients undergoing islet after kidney transplantation.</brief_summary>
	<brief_title>Islet After Kidney Transplant for Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients with type 1 diabetes mellitus, who have a stable functioning renal transplant, are taking the appropriate maintenance immunosuppression and have no severe health problems that preclude them receiving an islet transplant will be considered for inclusion. Have a history of or findings suggestive of unstable diabetic complications (e.g. active eye disease) Active infections (clinically or by laboratory testing) History of current malignancy or suspicion of malignancy until properly investigated and excluded Liver or biliary abnormalities Unstable cardiovascular disease Findings to suggest immunological sensitization or those women who have the potential to get pregnant and are not using a sufficient method of contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Islet transplantation</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>Kidney Transplantation</keyword>
</DOC>